These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Reznik I; Sirota P J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401 [TBL] [Abstract][Full Text] [Related]
45. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. Arnold LM; Mutasim DF; Dwight MM; Lamerson CL; Morris EM; McElroy SL J Clin Psychopharmacol; 1999 Feb; 19(1):15-8. PubMed ID: 9934938 [TBL] [Abstract][Full Text] [Related]
46. Fluvoxamine treatment of trichotillomania. Stanley MA; Breckenridge JK; Swann AC; Freeman EB; Reich L J Clin Psychopharmacol; 1997 Aug; 17(4):278-83. PubMed ID: 9241007 [TBL] [Abstract][Full Text] [Related]
47. Personality disorder scores improve with effective pharmacotherapy of depression. Black KJ; Sheline YI J Affect Disord; 1997 Mar; 43(1):11-8. PubMed ID: 9127826 [TBL] [Abstract][Full Text] [Related]
48. High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Ohkubo T; Shimoyama R; Otani K; Yoshida K; Higuchi H; Shimizu T Anal Sci; 2003 Jun; 19(6):859-64. PubMed ID: 12834224 [TBL] [Abstract][Full Text] [Related]
49. [The status of fluvoxamine among the antidepressive agents]. Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197 [TBL] [Abstract][Full Text] [Related]
50. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis]. De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R Encephale; 1997; 23(1):48-55. PubMed ID: 9172968 [TBL] [Abstract][Full Text] [Related]
52. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them? Schaller JL; Behar D; Chamberlain T J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477 [No Abstract] [Full Text] [Related]
53. Beneficial effects of fluvoxamine for hemiballism in a patient with depressive disorder: a case report. Cayköylü A; Albayrak Y; Uğurlu GK; Ekinci O Acta Neurol Belg; 2011 Mar; 111(1):62-5. PubMed ID: 21510237 [No Abstract] [Full Text] [Related]
54. [Fluoxetine versus fluvoxamine for treatment of chronic pain]. Ciaramella A; Grosso S; Poli P Minerva Anestesiol; 2000; 66(1-2):55-61. PubMed ID: 10736983 [TBL] [Abstract][Full Text] [Related]
55. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Zanardi R; Franchini L; Gasperini M; Smeraldi E; Perez J Int Clin Psychopharmacol; 1997 Jul; 12(4):195-7. PubMed ID: 9347379 [TBL] [Abstract][Full Text] [Related]
56. A case of adolescent body dysmorphic disorder treated with fluvoxamine. Khan S; Decker D J Child Adolesc Psychopharmacol; 2001; 11(1):105-7. PubMed ID: 11322739 [No Abstract] [Full Text] [Related]
57. Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. Rapaport MH; Judd LL J Affect Disord; 1998 Mar; 48(2-3):227-32. PubMed ID: 9543213 [TBL] [Abstract][Full Text] [Related]
58. Fluvoxamine-associated oscillopsia and a role for personalized medication dosing. Singman EL; Hocum B; Yohannan J; Pearson V Drug Metab Pers Ther; 2015 Dec; 30(4):271-5. PubMed ID: 26351962 [TBL] [Abstract][Full Text] [Related]
59. Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression. Oswald P; Souery D; Mendlewicz J Int J Neuropsychopharmacol; 2003 Mar; 6(1):85-7. PubMed ID: 12899739 [No Abstract] [Full Text] [Related]
60. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]